SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Dallas, TX.

United States Antimony Corp.

United States Antimony Corp. is trending due to significant community excitement surrounding its recent transition to full operational capacity, highlighted by successful defense contract shipments and new facility commissions. Investors are actively debating the company's long-term potential as a critical domestic supplier amid heightened geopolitical tensions and supply chain concerns.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

General Motors is trending as investors react to a pivotal earnings report that topped estimates and featured a dividend hike, alongside a fresh multi-billion dollar buyback program. The community is actively debating the company's long-term profitability as it pivots away from aggressive EV investments toward traditional truck and SUV segments while navigating new tariff pressures.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is currently a focus for investors as the company balances strong demand for grain-oriented electrical steel in data center and infrastructure projects against broader market concerns regarding its debt load and profitability. While some community members anticipate a squeeze fueled by significant short interest and upcoming earnings, others remain wary of ongoing price manipulation and potential management performance issues.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrop Grumman is in the spotlight as investors analyze mixed Q2 earnings, a raised guidance, and ongoing margin pressure within the Sentinel program. While the broader defense sector continues to navigate geopolitical tensions and government spending debates, the community is actively debating whether the recent price action represents a healthy pullback or a more significant shift in the stock's long-term value narrative.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Charles Schwab is trending as investors express significant frustration over repeated platform outages and technical issues that have hindered their ability to trade. The community is actively discussing a decline in platform reliability since the acquisition of TD Ameritrade, leading many to weigh alternatives like Interactive Brokers, Robinhood, or Webull for more stable execution.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Abeona Therapeutics is trending as investors react to the activation of its fifth qualified treatment center for ZEVASKYN, marking a critical step in scaling the commercial launch for RDEB. The community is actively discussing the stock's long-term commercial potential, institutional accumulation, and the ongoing battle between significant short interest and bullish sentiment regarding the company's path to profitability.

LightPath Technologies, Inc. engages in the design, development, manufacture, and distribution of optical and infrared components. Its products include molded glass and assemblies, infrared molded lenses, diamond turned, conventional ground and polished ground lenses and assemblies, and collimator assemblies, which are used in applications involving light detection and ranging technology. The firm supports a range of customers in the field of industrial, laser, defense, medical, telecommunications, and instrumentation. The company was founded in1985 and is headquartered in Orlando, FL.

Lightpath Technologies, Inc. - Ordinary Shares - Class A

LightPath Technologies is trending as investors bet on the company securing the U.S. Army's Next Generation Short Range Interceptor (NGSRI) contract, buoyed by its critical role in replacing restricted Chinese-sourced materials like germanium with domestic BlackDiamond glass. Community members are actively highlighting the company's deepening integration into key defense platforms, drone supply chains, and space-based optical systems as catalysts for a potential long-term valuation re-rating.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is seeing heightened activity following the commercial launch of NEREUS for motion sickness and ongoing community speculation regarding potential acquisition interest from major pharmaceutical players. While investors remain engaged with the company's GLP-1 adjunct pipeline and recent regulatory milestones, discussions are also dominated by debate over management's aggressive regulatory strategy and the impact of persistent stock price volatility.

Themes ETF Trust - Leverage Shares 2X Long SPCX Daily ETF

Leverage Shares 2x Long SPCX Daily ETF

The SPCH 2x Long SpaceX ETF is seeing intense trading activity and extreme volatility as investors capitalize on rapid price swings in the underlying shares. Community members are actively debating the merits of scalping the 2x leveraged product during high-profile news events while warning that these daily reset instruments require disciplined short-term trading strategies rather than long-term holds.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending following an SEC disclosure confirming Nvidia holds a 9.3% passive stake, a development that investors view as strong institutional validation of the company's long-term AI cloud infrastructure strategy. While bears continue to debate the impact of broader AI sector volatility and past equity deals, the community is focused on the potential for a short squeeze and analyst upgrades that highlight Nebius's growing competitive moat.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Turn Therapeutics Stock Trading Higher Today?

Turn Therapeutics expanded its GX-03 Phase 2 trial after interim data supported efficacy across a broader atopic dermatitis population.read more...

Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis

Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced the completion of a comprehensive interim analysis of its ongoing adaptive Phase 2 clinical trial evaluating GX-03 for the...

Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis

Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced it will host a live webcast on Tuesday, July 7, 2026, to present key findings from the comprehensive interim analysis of its...

Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis

Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced interim analysis findings from the first 50 completed subjects enrolled in its ongoing randomized, double-blind, vehicle-controlled...

Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model

Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company focused on developing localized therapies for inflammatory and infectious skin diseases, today announced the publication of a peer-reviewed research article in the Journal of Dermatological Treatment evaluating the...

Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026

Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief...

Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead

Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced the appointment of Stephen M...

Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies for dermatologic conditions, today reported financial...

Turn Therapeutics (NASDAQ:TTRX) Trading 6% Higher   - Should You Buy?

Turn Therapeutics (NASDAQ:TTRX) Shares Up 6% - Here's Why...

Turn Therapeutics (NASDAQ:TTRX) Issues Earnings Results

Turn Therapeutics (NASDAQ:TTRX - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.09) EPS for the quarter...

Turn Therapeutics, Inc. is a pharmaceutical and medical device development company. Its primary development programs focus on dermatological diseases. The company was founded by Bradley Burnam on January 6, 2015 and is headquartered in Westlake Village, CA.

Turn Therapeutics Inc.

Why Is Turn Therapeutics Stock Soaring Over 370% Premarket Today?

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

TTRXTurn Therapeutics Inc

Fundamentals

Latest TTRX News